These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 27757953)

  • 41. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update.
    Hliwa A; Ramos-Molina B; Laski D; Mika A; Sledzinski T
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis.
    van Meer S; van Erpecum KJ; Sprengers D; Klümpen HJ; Jansen PL; Ijzermans JN; Siersema PD; de Man RA; Verheij J
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):955-62. PubMed ID: 27196679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease.
    Haas JT; Francque S; Staels B
    Annu Rev Physiol; 2016; 78():181-205. PubMed ID: 26667070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease.
    Jiang M; Wu N; Chen X; Wang W; Chu Y; Liu H; Li W; Chen D; Li X; Xu B
    J Int Med Res; 2019 Apr; 47(4):1453-1466. PubMed ID: 30871397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathology of non-alcoholic fatty liver disease.
    Cataldo I; Sarcognato S; Sacchi D; Cacciatore M; Baciorri F; Mangia A; Cazzagon N; Guido M
    Pathologica; 2021 Jun; 113(3):194-202. PubMed ID: 34294937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
    Cuadrado A; Orive A; García-Suárez C; Domínguez A; Fernández-Escalante JC; Crespo J; Pons-Romero F
    Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease].
    Kwon OS; Kim JH; Kim JH
    Korean J Gastroenterol; 2017 Jun; 69(6):348-352. PubMed ID: 28637103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present.
    Jacobs A; Warda AS; Verbeek J; Cassiman D; Spincemaille P
    Curr Protoc Mouse Biol; 2016 Jun; 6(2):185-200. PubMed ID: 27248434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrative transcriptomic analysis of NAFLD animal model reveals dysregulated genes and pathways in metabolism.
    Yang W; He Y; Liu S; Gan L; Zhang Z; Wang J; Liang J; Dong Y; Wang Q; Hou Z; Yang L
    Gene; 2016 Dec; 595(1):99-108. PubMed ID: 27697615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Degasperi E; Colombo M
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis.
    van der Graaff D; Kwanten WJ; Francque SM
    Med Hypotheses; 2019 Jan; 122():188-197. PubMed ID: 30593409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
    Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
    Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice.
    Jeong HS; Kim KH; Lee IS; Park JY; Kim Y; Kim KS; Jang HJ
    Biomed Pharmacother; 2017 Apr; 88():625-634. PubMed ID: 28142119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic aspects of NAFLD pathogenesis.
    Naik A; Košir R; Rozman D
    Genomics; 2013 Aug; 102(2):84-95. PubMed ID: 23545492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.